After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Mineralys Therapeutics Inc is $1.94B. A total of 8.64 million shares were traded on the day, compared to an average of 1.06M shares.
In the most recent transaction, Rodman David Malcom sold 11,365 shares of MLYS for 12.93 per share on Aug 13 ’25. After the transaction, the Chief Medical Officer now owns 92,891 company shares. In a previous transaction on Aug 13 ’25, Rodman David Malcom bought 11,365 shares at 12.93 per share.
Among the insiders who sold shares, Levy Adam Scott disposed of 59,925 shares on Jul 30 ’25 at a per-share price of $14.76. This resulted in the CFO and Secretary holding 132,934 shares of MLYS after the transaction. In another insider transaction, Levy Adam Scott sold 12,946 shares at $14.04 per share on Jul 28 ’25. Company shares held by the CFO and Secretary now total 193,666.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, MLYS has a high of $30.14 and a low of $8.24.
As of this writing, MLYS has an earnings estimate of -$0.65 per share for the current quarter. EPS was calculated based on a consensus of 7.0 estimates, with a high estimate of -$0.51 per share and a lower estimate of -$0.74. The company reported an EPS of -$1.13 in the last quarter
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. MLYS’s latest balance sheet shows that the firm has $10.61M in Cash & Short Term Investments as of fiscal 2021. There were $4.50M in debt and $5.05M in liabilities at the time. Its Book Value Per Share was $4.77, while its Total Shareholder’s Equity was -$22.93M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MLYS is Buy with a score of 4.50.
